Novo Nordisk ® es care sales growth is driven by GLP-1 patients and value market share in IO Number of patients (millions) Class growth ~45% Value market share 6 75% 67.0% 5 60% 4 3 2 1 0 May-21 May-22 44.6% 45% 30.0% 30% 11.6% 15% 10.8% 0% May-23 GLP-1 patients Rybelsus ® Ozempic ® dulaglutide wan; RoW: Rest of World; CER: Constant exchange rates ar’ 23- May’23 vs Mar’22 - May’22 (Rolling 3 -month average) age daily doses Victoza ® NN GLP-1
Download PDF file